CY1124191T1 - Θεραπεια της νοσου μοσχευματος εναντια στον ξενιστη σε μεταμοσχευμενους ασθενεις - Google Patents

Θεραπεια της νοσου μοσχευματος εναντια στον ξενιστη σε μεταμοσχευμενους ασθενεις

Info

Publication number
CY1124191T1
CY1124191T1 CY20211100473T CY211100473T CY1124191T1 CY 1124191 T1 CY1124191 T1 CY 1124191T1 CY 20211100473 T CY20211100473 T CY 20211100473T CY 211100473 T CY211100473 T CY 211100473T CY 1124191 T1 CY1124191 T1 CY 1124191T1
Authority
CY
Cyprus
Prior art keywords
host disease
versary
grafv
treatment
transplant patients
Prior art date
Application number
CY20211100473T
Other languages
Greek (el)
English (en)
Inventor
Peter Gergely
Kazuhiko Kuriyama
Original Assignee
Priothera Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Priothera Limited filed Critical Priothera Limited
Publication of CY1124191T1 publication Critical patent/CY1124191T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01BSOIL WORKING IN AGRICULTURE OR FORESTRY; PARTS, DETAILS, OR ACCESSORIES OF AGRICULTURAL MACHINES OR IMPLEMENTS, IN GENERAL
    • A01B1/00Hand tools
    • A01B1/02Spades; Shovels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/145Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/664Amides of phosphorus acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/28Mercury; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13Cyclosporins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/32Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/06Phosphorus compounds without P—C bonds
    • C07F9/08Esters of oxyacids of phosphorus
    • C07F9/09Esters of phosphoric acids
    • C07F9/094Esters of phosphoric acids with arylalkanols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Environmental Sciences (AREA)
  • Soil Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20211100473T 2013-02-20 2021-06-01 Θεραπεια της νοσου μοσχευματος εναντια στον ξενιστη σε μεταμοσχευμενους ασθενεις CY1124191T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361766830P 2013-02-20 2013-02-20
PCT/IB2014/059067 WO2014128611A1 (en) 2013-02-20 2014-02-18 Treatment of graft versus host disease in transplant patients

Publications (1)

Publication Number Publication Date
CY1124191T1 true CY1124191T1 (el) 2022-05-27

Family

ID=50236228

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100473T CY1124191T1 (el) 2013-02-20 2021-06-01 Θεραπεια της νοσου μοσχευματος εναντια στον ξενιστη σε μεταμοσχευμενους ασθενεις

Country Status (23)

Country Link
US (2) US20160000811A1 (enExample)
EP (1) EP2958624B1 (enExample)
JP (2) JP6441822B2 (enExample)
KR (1) KR102165514B1 (enExample)
CN (1) CN105007981B (enExample)
AU (1) AU2014220377B2 (enExample)
BR (1) BR112015019197A2 (enExample)
CA (1) CA2898565C (enExample)
CY (1) CY1124191T1 (enExample)
DK (1) DK2958624T3 (enExample)
EA (1) EA030783B1 (enExample)
ES (1) ES2873181T3 (enExample)
HR (1) HRP20210891T1 (enExample)
HU (1) HUE054330T2 (enExample)
LT (1) LT2958624T (enExample)
MX (1) MX369631B (enExample)
PL (1) PL2958624T3 (enExample)
PT (1) PT2958624T (enExample)
RS (1) RS61933B1 (enExample)
SI (1) SI2958624T1 (enExample)
SM (1) SMT202100334T1 (enExample)
TW (1) TWI648050B (enExample)
WO (1) WO2014128611A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018017134A2 (pt) * 2016-03-08 2019-01-15 Kyorin Seiyaku Kk tratamento de pacientes com transplante de célula-tronco hematopoiética
US20210283073A1 (en) * 2018-07-27 2021-09-16 Priothera Limited Agent for inhibiting recurrence of hematological malignancy in patients who have undergone hematopoietic stem cell transplantation
CN117177748A (zh) * 2020-11-04 2023-12-05 浩康生物系统公司 用于异基因造血干细胞移植的方法
TW202245741A (zh) 2021-01-28 2022-12-01 法商普萊歐塞拉公司 使用s1p受體調節劑之治療方法
AU2021424131A1 (en) 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
CA3250985A1 (en) 2022-02-16 2023-08-24 Priothera Sas CAR CELL TREATMENT METHODS IN COMBINATION WITH S1P RECEIVER MODULATORS
EP4282407A1 (en) 2022-05-27 2023-11-29 Priothera SAS Treatment of cancer with s1p receptor agonists
WO2025109119A1 (en) 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011694A4 (en) * 1996-11-15 2000-11-15 Baxter Int TREATMENT FOR ALLOGENIC STEM CELL TRANSPLANTATION
JPH11343242A (ja) * 1998-03-30 1999-12-14 Otsuka Pharmaceut Co Ltd 造血幹細胞移植用剤
US6383481B1 (en) 1998-03-30 2002-05-07 Japan Immunoresearch Laboratories Co., Ltd. Method for transplantation of hemopoietic stem cells
CA2461212C (en) * 2001-09-27 2010-08-17 Kyorin Pharmaceutical Co., Ltd. Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same
EP1548003A4 (en) * 2002-09-19 2006-06-07 Kyorin Seiyaku Kk AMINO ALCOHOL DERIVATIVE, ADDITIONAL SALT AND IMMUNOSUPPRESIVE AGENT
US7781617B2 (en) * 2004-07-16 2010-08-24 Kyorin Pharmaceutical Co., Ltd Effective use method of medicaments and method of preventing expression of side effect
WO2006073126A1 (ja) * 2005-01-06 2006-07-13 Kissei Pharmaceutical Co., Ltd. 慢性移植片対宿主症におけるドライアイの予防および治療剤
WO2011140170A1 (en) 2010-05-04 2011-11-10 Yeda Research And Development Co. Ltd. Immunotherapy using redirected allogeneic cells
CA2794607A1 (en) 2010-05-06 2011-11-10 Novartis Ag Dosage regimen of diaryl sulfide derivatives

Also Published As

Publication number Publication date
KR20150118149A (ko) 2015-10-21
MX2015010833A (es) 2016-07-08
US20180153911A1 (en) 2018-06-07
JP6441822B2 (ja) 2018-12-19
ES2873181T3 (es) 2021-11-03
EA201591522A1 (ru) 2016-03-31
HRP20210891T1 (hr) 2021-07-23
TWI648050B (zh) 2019-01-21
DK2958624T3 (da) 2021-06-07
SI2958624T1 (sl) 2021-07-30
EP2958624B1 (en) 2021-05-12
BR112015019197A2 (pt) 2017-07-18
AU2014220377B2 (en) 2017-05-04
RS61933B1 (sr) 2021-07-30
JP6633170B2 (ja) 2020-01-22
EP2958624A1 (en) 2015-12-30
JP2019059748A (ja) 2019-04-18
PL2958624T3 (pl) 2021-10-04
MX369631B (es) 2019-11-14
SMT202100334T1 (it) 2021-07-12
AU2014220377A1 (en) 2015-08-06
HUE054330T2 (hu) 2021-09-28
KR102165514B1 (ko) 2020-10-15
PT2958624T (pt) 2021-06-11
CN105007981A (zh) 2015-10-28
US11224604B2 (en) 2022-01-18
CA2898565A1 (en) 2014-08-28
TW201511751A (zh) 2015-04-01
LT2958624T (lt) 2021-08-10
CN105007981B (zh) 2020-07-21
WO2014128611A1 (en) 2014-08-28
JP2016509050A (ja) 2016-03-24
CA2898565C (en) 2023-01-24
EA030783B1 (ru) 2018-09-28
US20160000811A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
CY1124191T1 (el) Θεραπεια της νοσου μοσχευματος εναντια στον ξενιστη σε μεταμοσχευμενους ασθενεις
IL270982A (en) Articles of manufacture and methods for treatment using adoptive cell therapy
MX2014003832A (es) Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo.
EA201591501A1 (ru) Терапевтические средства на основе csf-1
EA201500314A1 (ru) Лекарственные формы энзалутамида
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
BR112014031424A2 (pt) tratamento de células pluripotentes
EA201600252A1 (ru) Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования
UY33956A (es) Anticuerpo del factor antitisular humano y sus usos para tratar cáncer
MX2016005824A (es) Metodo de cultivo celular.
CY1123144T1 (el) Επαγωγη καρδιακης αναγεννησης μe microrna
CR20150585A (es) Anticuerpos anti-igf-1r con abolición de la unión al fcrn y su utilización en el tratamiento de enfermedades oculares vasculares
IL245936A0 (en) Methods of treating hematological cancers and predicting clinical sensitivity to leanlidomide using biomarkers
MX2016013910A (es) Tratamiento del cancer.
EA201490509A1 (ru) Биосовместимый катетер
MX378857B (es) Celulas huespedes modificadas y usos de las mismas.
CO7151543A2 (es) Combinaciones terapéuticas y métodos para tratar el melanoma
EA201591796A1 (ru) Антитела к cd52
MX2015008436A (es) Composiciones para permeabilizar celulas sanguineos fijos y sus usos.
MX2016001439A (es) Composiciones y metodos para identificar un riesgo de cancer en un sujeto.
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
MX2021010546A (es) Composiciones y metodos para tratamiento de la piel.
TR201811308T4 (tr) Kanser kok hücrelerini azaltan anti-emp2 tedavisi.
MX358726B (es) Biomarcador predictivo de supervivencia en el tratamiento de carcinoma de celulas renales.
BR112015000547A2 (pt) métodos para tratar tecido; e composição de tecido